Prothena Corporation PLC
PRTA6.880USD
+0.070+1.03%
Market hours （ET）Quotes delayed by 15 min
370.33MMarket Cap
LossP/E TTM
More Details of Prothena Corporation PLC Company
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Company Info
Ticker SymbolPRTA
Company nameProthena Corporation PLC
IPO dateDec 21, 2012
CEODr. Gene G. Kinney, Ph.D.
Number of employees163
Security typeOrdinary Share
Fiscal year-endDec 21
Address77 Sir John Rogerson's Quay, Block C
CityDUBLIN
Stock exchangeNASDAQ Global Select Consolidated
CountryIreland
Postal codeD02 VK60
Phone35312362500
Websitehttps://www.prothena.com/
Ticker SymbolPRTA
IPO dateDec 21, 2012
CEODr. Gene G. Kinney, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
--
--
Ms. Karin L. Walker, CPA
Ms. Karin L. Walker, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Paula K. Cobb
Ms. Paula K. Cobb
Independent Director
Independent Director
--
--
Ms. Helen S. Kim
Ms. Helen S. Kim
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jun 7
Updated: Sat, Jun 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.75%
Scully (William P)
10.42%
Fennell (Todd W.)
8.53%
T. Rowe Price Associates, Inc.
6.29%
BlackRock Institutional Trust Company, N.A.
6.10%
Other
53.91%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.75%
Scully (William P)
10.42%
Fennell (Todd W.)
8.53%
T. Rowe Price Associates, Inc.
6.29%
BlackRock Institutional Trust Company, N.A.
6.10%
Other
53.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.72%
Individual Investor
18.99%
Hedge Fund
12.64%
Investment Advisor/Hedge Fund
10.92%
Venture Capital
5.48%
Research Firm
2.58%
Bank and Trust
0.65%
Pension Fund
0.21%
Sovereign Wealth Fund
0.11%
Other
6.70%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
457
50.26M
93.38%
-20.92M
2025Q1
472
64.29M
119.45%
-7.39M
2024Q4
479
65.24M
121.19%
+239.99K
2024Q3
476
59.39M
110.43%
-5.39M
2024Q2
479
58.48M
108.76%
-4.67M
2024Q1
472
60.86M
113.29%
-264.94K
2023Q4
474
56.64M
105.77%
-2.21M
2023Q3
476
55.90M
104.65%
-1.73M
2023Q2
475
55.02M
104.46%
-3.12M
2023Q1
464
54.98M
104.68%
-658.88K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
7.94M
14.75%
-129.91K
-1.61%
Mar 31, 2025
Scully (William P)
5.61M
10.42%
-36.34K
-0.64%
Mar 31, 2025
Fennell (Todd W.)
4.59M
8.53%
-54.34K
-1.17%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.38M
6.29%
-232.75K
-6.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.29M
6.1%
-61.73K
-1.84%
Mar 31, 2025
Logos Global Management LP
2.95M
5.48%
+2.95M
--
May 29, 2025
Armistice Capital LLC
2.20M
4.08%
-40.00K
-1.79%
Mar 31, 2025
Palo Alto Investors LP
1.66M
3.08%
-78.23K
-4.50%
Mar 31, 2025
State Street Global Advisors (US)
1.52M
2.83%
-340.28K
-18.28%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.28M
2.38%
+183.72K
+16.70%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.08%
iShares Neuroscience and Healthcare ETF
0.63%
Invesco NASDAQ Future Gen 200 ETF
0.6%
Tema Neuroscience and Mental Health ETF
0.3%
Federated Hermes MDT Small Cap Core ETF
0.3%
ALPS Medical Breakthroughs ETF
0.22%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.08%
iShares Neuroscience and Healthcare ETF
Proportion0.63%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.6%
Tema Neuroscience and Mental Health ETF
Proportion0.3%
Federated Hermes MDT Small Cap Core ETF
Proportion0.3%
ALPS Medical Breakthroughs ETF
Proportion0.22%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
